Bio-Techne Crecimiento futuro
Future controles de criterios 3/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Bio-Techne de 21.1% y 6.5% por año respectivamente. Se prevé que el BPA crezca en un 21.2% al año. Se espera que la rentabilidad financiera sea de 14.4% en 3 años.
Información clave
21.1%
Tasa de crecimiento de los beneficios
21.19%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Life Sciences | 16.9% |
| Tasa de crecimiento de los ingresos | 6.5% |
| Rentabilidad financiera futura | 14.43% |
| Cobertura de analistas | Good |
| Última actualización | 26 Jun 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Artículo de análisis • Jun 18
Bio-Techne (TECH) Stock Could Be 10.4% Undervalued After Refeyn Collaboration
Bio-Techne (TECH) stock has been in focus after the company partnered with Refeyn on a four hour workflow that links charge heterogeneity, molecular weight, and aggregation in bispecific antibodies and biosimilars at single molecule resolution. See our latest analysis for Bio-Techne. Alongside the Refeyn partnership, Bio-Techne’s recent share price return of 23.79% over 30 days contrasts with a year to date share price decline of 7.80%, while the 1 year total shareholder return of 10.38% sits...
Actualización de narrativa • Jun 17
TECH: Portfolio Rebrand And Exosome Exit Will Support Future Margin Upside
Analysts have trimmed their Bio-Techne price target slightly from $76.00 to $75.00, reflecting updated views on revenue growth, discount rate and profit margin assumptions, while keeping long term P/E expectations broadly similar. What’s in the News for Bio-Techne Bio-Techne reported 3% organic revenue growth in Q4 fiscal 2025 and maintained profitability in what management described as challenging market conditions, according to its Q4 2025 earnings transcript.
Actualización de narrativa • Jun 03
TECH: Spatial Biology Platforms And Brand Simplification Will Support A Steady Forward Outlook
Analysts have lowered their price target on Bio-Techne from $75.25 to $61.42, citing updated assumptions that include slightly lower revenue growth, modestly higher profit margins, and a reduced future P/E multiple. What's in the News Bio-Techne stock rallied about 12% over a recent five day period, adding roughly US$780 million in market value to reach around US$7.5b in market capitalization, according to recent coverage.Actualización de narrativa • May 12
TECH: Portfolio Rebrand And Diagnostics Expansion Will Support Stronger Future Upside
Analysts have adjusted their price target on Bio-Techne to $76.00 from $75.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Bio-Techne introduced a streamlined brand architecture that groups its offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, to align products with stages of scientific research from discovery through clinical diagnostics (Key Developments).
Actualización de narrativa • Apr 20
TECH: Spatial And Clinical Platforms Will Support Balanced Future Earnings Potential
Analysts have reset their price targets on Bio-Techne to $56.78 from $65.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Rolled out a new brand architecture that organizes offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics.Actualización de narrativa • Apr 05
TECH: Clinical And Spatial Biology Platforms Will Support Higher Future Earnings Multiple
Analysts have trimmed their price target on Bio-Techne to about $65, with updated assumptions reflecting slightly adjusted discount rates, revenue growth expectations, profit margins, and a modest shift in projected future P/E levels. What's in the News Expanded COMET spatial biology portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits, plus updated HORIZON Image Analysis Software to support more flexible and sensitive tissue analysis workflows (Key Developments).Actualización de narrativa • Mar 22
TECH: Clinical Platform Adoption Will Support Higher Future Earnings Multiple
Analysts have lifted their price target on Bio-Techne to $65.41, citing updated assumptions that reflect slightly higher projected revenue growth, a modestly stronger profit margin, and a small adjustment to the discount rate and future P/E expectations. What's in the News Ella benchtop immunoassay platform receives CE-IVD marking and becomes available for clinical use in the European Union, supporting in-house test development, clinical trials, and translational activities on a validated platform (Key Developments).Actualización de narrativa • Mar 06
TECH: Multiomic Platform Expansion Will Support Higher Future Earnings Multiple
Analysts have raised their price target for Bio-Techne to $65.41 from $61.03, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. What's in the News The Ella benchtop immunoassay platform received CE-IVD marking, making it available for clinical use in the European Union and positioning it as an option for in-house test development, clinical trials, and other translational activities (Key Developments).Actualización de narrativa • Feb 20
TECH: Multiomic Platforms And 3D Workflows Will Support A Steady Forward Outlook
Narrative Update on Bio-Techne Analysts have adjusted their price target on Bio-Techne from $70.00 to $75.25, citing updated assumptions for revenue growth, profit margin, discount rate and future P/E that collectively support a higher assessed fair value. What’s in the News Ella benchtop immunoassay platform received CE-IVD marking and is now available for clinical use in the European Union.Artículo de análisis • Feb 12
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings
Shareholders appeared unconcerned with Bio-Techne Corporation's ( NASDAQ:TECH ) lackluster earnings report last week...Actualización de narrativa • Feb 05
TECH: Multiomic Platform Progress Will Contrast With Excessive Long Term Earnings Multiple
Analysts have lifted their fair value estimate for Bio-Techne by roughly $0.72 to reflect slightly stronger assumptions on revenue growth, profit margins, and the discount rate, along with a modestly lower future P/E. What's in the News Bio-Techne launched Cultrex Synthetic Hydrogel, a fully defined synthetic extracellular matrix aimed at more reproducible and scalable 3D stem cell and organoid research, reducing reliance on animal component derived matrices and supporting new approach methodologies in drug screening, toxicology, and personalized medicine (Key Developments).Actualización de narrativa • Jan 22
TECH: Multiomic Automation And Buybacks Will Support A Steady Forward Outlook
Narrative Update on Bio-Techne Analysts have nudged their fair value estimate for Bio-Techne to US$70.00 per share from about US$69.17, citing updated assumptions around discount rates, long term revenue growth, profit margins and future P/E expectations. What's in the News Spatial biology brand Lunaphore is partnering with the Wyss Center for Bio and Neuroengineering in Geneva to build an automated workflow for simultaneous RNA and protein detection in 3D specimens.Seeking Alpha • Jan 08
Bio-Techne: Recovery Likely Coming, But Is There Enough Re-Rating Potential?
Summary Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research activity. Margin pressures from past acquisitions are easing; exiting Exosome Diagnostics and productivity initiatives should drive operating leverage and margin improvement. I expect revenue growth to reaccelerate to high single digits by mid-year, but valuation remains stretched, with fair value seen in the $60s. I am shifting to a more cautious stance, as upside appears limited without a significant inflection in revenue or margin expansion. Read the full article on Seeking AlphaActualización de narrativa • Jan 08
TECH: Multiomic Partnerships And Automation Will Support A Steady Forward Outlook
Analysts have kept their fair value estimate for Bio-Techne steady at about US$69.17, with small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions driving a refined but directionally unchanged price target view. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, targeting higher resolution multiomic analysis in intact samples and broader use of spatial biology tools in research and diagnostics (Key Developments).Actualización de narrativa • Dec 16
TECH: Multiomic Expansion And Margin Improvement Will Support Balanced Future Outlook
Analysts have raised their price target on Bio-Techne from approximately 53 dollars to about 60 dollars, citing expectations for modestly faster revenue growth, improving profit margins, and a higher justified future price to earnings multiple. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, aiming to extend multiomic spatial biology from 2D into 3D and reduce reliance on animal models (Key Developments).Actualización de narrativa • Dec 01
TECH: Share Buyback Completion And New Partnerships Will Maintain Steady Outlook
Analysts have maintained Bio-Techne's price target at $69.17, citing minor adjustments to discount rate and forward P/E assumptions. Overall sentiment and company outlook remain steady.Actualización de narrativa • Nov 17
TECH: Share Buyback Momentum Will Drive Stronger Performance Ahead
Narrative Update on Bio-Techne Analysts have increased their price target for Bio-Techne from $67.83 to $69.17, citing improved revenue growth and higher projected profit margins as key drivers behind the upward adjustment. What's in the News Bio-Techne successfully repurchased 500,000 shares between July and September 2025, completing a $124.06 million buyback under its May 2025 program (Buyback Tranche Update).Artículo de análisis • Nov 08
Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Bio-Techne Corporation ( NASDAQ:TECH ) shareholders are probably feeling a little disappointed, since its shares fell...Actualización de narrativa • Nov 03
TECH: Product Advances And Index Changes Will Influence Future Demand For Precision Tools
Analysts have nudged their price target for Bio-Techne higher, raising it by $0.75 to $67.83. They cite modest improvements in profitability expectations and a slightly increased fair value assessment.Actualización de narrativa • Oct 20
Chronic Disease Trends And Precision Medicine Will Shape Demand
Narrative Update on Bio-Techne Analysts have raised their price target for Bio-Techne from $66.23 to $67.08. This change reflects modest improvements in profit margin expectations, even though revenue growth forecasts have been slightly reduced.Actualización de narrativa • Aug 27
Chronic Disease Trends And Precision Medicine Will Shape Demand
Bio-Techne's consensus price target saw only a minimal increase to $65.31, as both future P/E and revenue growth forecasts remained largely unchanged. What's in the News Bio-Techne formed a strategic partnership to distribute Spear Bio's ultrasensitive immunoassays, enabling detection of low-abundance biomarkers in neurology, initially focusing on translational research in Alzheimer's disease.Artículo de análisis • Jul 28
Investors Still Waiting For A Pull Back In Bio-Techne Corporation (NASDAQ:TECH)
Bio-Techne Corporation's ( NASDAQ:TECH ) price-to-earnings (or "P/E") ratio of 70x might make it look like a strong...Seeking Alpha • Feb 27
Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain
Summary Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue growth of 9%, with strength in both Protein Sciences and Diagnostics & Spatial Biology, with notable gains in spatial biology and cell therapy reagents. Academic research funding cuts may impact Bio-Techne to some extent, but its core consumables are essential and less price-sensitive, mitigating significant revenue loss. Bio-Techne is well-positioned for where biopharma wants to direct its R&D budgets, including biologics, cell/gene therapy, bioproduction, and process automation. Valuation has long been a sticking point with Bio-Techne shares; I can't call 8x forward revenue "cheap", but it's about as cheap as the shares get and the business remains on a good trajectory. Read the full article on Seeking AlphaPrevisiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 6/30/2028 | 1,379 | 256 | 332 | 378 | 9 |
| 6/30/2027 | 1,265 | 220 | 367 | 402 | 12 |
| 6/30/2026 | 1,209 | 184 | 269 | 334 | 14 |
| 3/31/2026 | 1,211 | 109 | 270 | 295 | N/A |
| 12/31/2025 | 1,216 | 81 | 223 | 249 | N/A |
| 9/30/2025 | 1,217 | 78 | 224 | 251 | N/A |
| 6/30/2025 | 1,220 | 73 | 257 | 288 | N/A |
| 3/31/2025 | 1,209 | 132 | 221 | 265 | N/A |
| 12/31/2024 | 1,196 | 158 | 254 | 305 | N/A |
| 9/30/2024 | 1,172 | 151 | 245 | 303 | N/A |
| 6/30/2024 | 1,159 | 168 | 236 | 299 | N/A |
| 3/31/2024 | 1,154 | 203 | 251 | 307 | N/A |
| 12/31/2023 | 1,145 | 224 | 225 | 276 | N/A |
| 9/30/2023 | 1,144 | 247 | 215 | 258 | N/A |
| 6/30/2023 | 1,137 | 285 | 216 | 254 | N/A |
| 3/31/2023 | 1,124 | 271 | 233 | 274 | N/A |
| 12/31/2022 | 1,120 | 262 | 252 | 296 | N/A |
| 9/30/2022 | 1,118 | 292 | 285 | 333 | N/A |
| 6/30/2022 | 1,106 | 272 | 280 | 325 | N/A |
| 3/31/2022 | 1,076 | 225 | 302 | 345 | N/A |
| 12/31/2021 | 1,030 | 210 | 308 | 346 | N/A |
| 9/30/2021 | 985 | 177 | 295 | 335 | N/A |
| 6/30/2021 | 931 | 140 | 308 | 352 | N/A |
| 3/31/2021 | 848 | 184 | 225 | 275 | N/A |
| 12/31/2020 | 799 | 175 | 201 | 250 | N/A |
| 9/30/2020 | 760 | 248 | 179 | 231 | N/A |
| 6/30/2020 | 739 | 229 | 153 | 205 | N/A |
| 3/31/2020 | 755 | 187 | 170 | 216 | N/A |
| 12/31/2019 | 745 | 195 | N/A | 207 | N/A |
| 9/30/2019 | 734 | 93 | N/A | 183 | N/A |
| 6/30/2019 | 714 | 96 | N/A | 182 | N/A |
| 3/31/2019 | 703 | 121 | N/A | 191 | N/A |
| 12/31/2018 | 682 | 96 | N/A | 173 | N/A |
| 9/30/2018 | 661 | 128 | N/A | 165 | N/A |
| 6/30/2018 | 643 | 126 | N/A | 170 | N/A |
| 3/31/2018 | 619 | 112 | N/A | 156 | N/A |
| 12/31/2017 | 599 | 114 | N/A | 160 | N/A |
| 9/30/2017 | 577 | 73 | N/A | 162 | N/A |
| 6/30/2017 | 563 | 76 | N/A | 144 | N/A |
| 3/31/2017 | 541 | 74 | N/A | 129 | N/A |
| 12/31/2016 | 528 | 82 | N/A | 141 | N/A |
| 9/30/2016 | 517 | 101 | N/A | 138 | N/A |
| 6/30/2016 | 499 | 104 | N/A | 144 | N/A |
| 3/31/2016 | 482 | 105 | N/A | 145 | N/A |
| 12/31/2015 | 465 | 99 | N/A | 138 | N/A |
| 9/30/2015 | 456 | 107 | N/A | 135 | N/A |
| 6/30/2015 | 452 | 108 | N/A | 139 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (21.1% al año) de TECH es superior a la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que los beneficios (21.1% al año) de TECH crezcan más rápidamente que el mercado US (18.4% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de TECH crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (6.5% al año) de TECH crezcan más despacio que el mercado de US (12.7% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 6.5% al año) de TECH crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de TECH sea baja dentro de 3 años (14.4%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/26 21:34 |
| Precio de las acciones al final del día | 2026/06/26 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/06/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Bio-Techne Corporation está cubierta por 27 analistas. 14 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| David Toung | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Robert Wasserman | Benchmark Company |